Fig. 6

Assessment of OV patient sensitivity to immunotherapy and chemotherapy. A The boxplots showed the expression difference of eight typical immune checkpoints (including CTLA4, CD274, HAVCR2, LAG3, PDCD1LG2, PDCD1, TIGIT, and SIGLEC15) between the two risk groups stratified by the autophagy-related signature. B Based on the Tumor Immune Dysfunction and Exclusion (TIDE) scoring system, we evaluated the sensitivity of OV patients towards immunotherapy. C The violin plots represented the estimated half-maximal inhibitory concentration (IC50) values of OV patients towards 8 typical chemotherapies, including Cisplatin, Paclitaxel, Bleomycin, Docetaxel, Gemcitabine, Sorafenib, Veliparib, and Vinblastine. The chemotherapy sensitivity analyses were carried out through the Genomics of Drug Sensitivity in Cancer database (GDSC). *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001; ****p-value < 0.0001